The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut/L'efficacité du palivizumab en situation réelle pour réduire les hospitalisations causées par le virus respiratoire syncytial chez les nourrissons qui habitent au Nunavut

The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut/L'efficacité du palivizumab en situation réelle pour réduire les hospitalisations causées par le virus respiratoire syncytial chez les nourrissons qui habitent au Nunavut

BACKGROUND/ Nunavut has the highest hospitalization rates for respiratory syncytial virus (RSV) worldwide, with rates of 166 per 1000 live births per year

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Canadian respiratory journal 2014-05, Vol.21 (3), p.185
Hauptverfasser: Banerji, Anna, Panzov, Vladimir, Young, Michael, Lee, Bonita E, Mamdani, Muhammad, Giles, B Louise, Dennis, Marguerite, Morel, Johanne, Bisson, Danny, Paes, Bosco A, Hui, Charles, Mahony, Jim
Format: Artikel
Sprache:eng
Schlagworte:
Effectiveness studies
Inuit
Monoclonal antibodies
Respiratory syncytial virus
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BACKGROUND/ Nunavut has the highest hospitalization rates for respiratory syncytial virus (RSV) worldwide, with rates of 166 per 1000 live births per year
ISSN:1198-2241
1916-7245